The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

HIV Drug ResistanceHIV Drug Resistance
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Which drugs in pipeline for multi-drug resistance?
Feb 11, 2004


Can you please let me know which drugs are in the pipeline and look very promising for multi-drug resistant HIV? Are any in Phase 3 of Clinical trials and for the ones in Phase 2, have they shown efficacy where currently available drugs ahve not?

Thanks very much!

Response from Dr. Sherer

There are promising agents in the pipeline for people with multi-drug resistance. The closest to approval is tipranivir, which is a protease inhibito with very good activity against most PI-resistant strains. It will require co-adminstration with ritonavir for boosting, and is currently in phase III trials following phase II dosing trials.

Other drugs somewhat further away from clinical use include two Tibotec compounds, i.e. TMC114, a next generation PI, and TMC 125, which is a second generation NNRTI with excellent activity against most viral strains that are resistant to current NNRTIs.

For further information regarding clinical trials, I suggest the clinical trials hot line (1-800-trialsA), or the NIH website,

Drug Resistance Development Possible?
Resistant With Good TCell Count

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint